Cardiovascular Disease Prevention Through Pharmaceutical LDL Reduction
By
brandonb
Sesame, salt, and substance. A flagship bake.
Summary
The article argues that cardiovascular disease (CVD) is effectively a solved problem due to modern pharmaceutical interventions. It explains that CVD progression depends on specific LDL particles (apoB and Lp(a)) becoming embedded in arterial walls, and that circulating lipoprotein levels are largely genetically determined with minimal lifestyle influence. The core claim is that current pharmaceuticals can dramatically reduce LDL levels to non-pathogenic levels, these treatments are safe and well-tolerated, and aggressive LDL reduction in young adults can permanently protect them from developing CVD with minimal downside.
Key quotes
· 5 pulledCardiovascular disease (CVD) is the leading cause of death in the developed world.
The progression of cardiovascular disease is fully dependent upon the retention of low-density lipoproteins (LDLs) into the arterial wall, triggering the growth of atherosclerotic plaques.
Only certain LDLs, namely those attached to apolipoprotein B (apoB) and apolipoprotein(a) (Lp(a)), tend to become pathologically embedded in the arterial wall in the course of their circulation in the bloodstream.
Circulating levels of lipoproteins are largely genetically determined, with minimal influence from lifestyle factors, and modern pharmaceuticals are capable of dramatically reducing LDL levels to those incapable of causing cardiovascular disease in the span of a human lifespan.
For young adults in relatively good health, aggressive LDL reduction will permanently protect them from developing cardiovascular disease with nearly zero downside.
You might also wanna read
Experimental pill daraxonrasib extends survival in advanced pancreatic cancer patients, study finds
Researchers reported that daraxonrasib, a novel experimental pill, helped patients with advanced pancreatic cancer live longer by blocking a
npr.org·6h ago
GeneSkin Develops mRNA Therapy Targeting Skin Stem Cells for Rejuvenation and Hair Growth
GeneSkin is developing a novel mRNA therapy targeting basal stem cells in the skin to address a wide range of dermatological issues includin
wyss.harvard.edu·9h ago
First human trial begins for drug that could regrow missing teeth
Kyoto University Hospital has launched the first human trial of TRG-035, a drug designed to regrow teeth in adults by blocking a protein tha
boingboing.net·1d ago
Japanese researchers develop vitamin K-like compounds that may help convert brain cells into neurons
Japanese researchers have developed a new family of vitamin K-like molecules that may help immature brain cells transition into neurons. Whi
zmescience.com·1d ago
International trial shows DNA test could help many breast cancer patients avoid chemotherapy
A new international trial presented at the American Society of Clinical Oncology conference suggests that millions of breast cancer patients
bbc.co.uk·1d ago
Cohort Study Evaluates Age at Onset and Family History as Predictors for Genetic Testing in Parkinson Disease
This cohort study evaluates the association between age at onset (AAO) and family history in Parkinson disease patients who carry pathogenic
doi.org·1d ago